De Novo, A New Day By Jack Cosentino I have spoken of the way Medibio’s objective diagnosis and monitoring of mental illness will change the landscape of mental health worldwide. Today marks another milestone in our progress toward [...]
Medibio Submits FDA De Novo Application Sydney, Australia and Minneapolis, MN USA – 16 July 2018: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, today announced the U.S. Food and Drug Administration (FDA) [...]
Peer-reviewed Neurology Publication on Medibio Science Medibio announces that a clinical article by Defillo et al. titled “Physiological Differences between Mood Disorder Phenotypes Based on Heart Rate Variability” has been published in EC Neurology, an internationally peer-reviewed journal. [...]
